Randomized Controlled Trial of Carvedilol versus Rabeprazol Administration in the prevention of Esophageal Variceal Bleeding After Esophageal Variceal Ligation

Randomized Controlled Trial of Carvedilol versus Rabeprazol Administration in the prevention of Esophageal Variceal Bleeding After Esophageal Variceal Ligation - Post-EVL Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003912

Enrollment

400

Registered

2010-07-15

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients after esophageal variceal ligation (EVL)

Interventions

Carbedilol Rabeprazol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Liver cirrhosis, Child A or B. (2)Esophageal variceal ligation within three months. (3)Systolic blood pressure is more than 130 mm Hg or dyastolic blood pressure in more than 80 mm Hg. (4)Heart rate is more than 60 bpm.

Exclusion criteria

Exclusion criteria: (1)Hepatocellular carcinoma (2)Refractory ascites and uncontrolled hepatic encephalopathy (3)Active alcoholism before 3 months (4)Portal thrombus (5)Severe hypertension:Systolic pressure is more than 160 mm Hg or diastolic pressure is more than 100 mm Hg. (6)Contraindication for B-blockers (7)Pregnancy

Design outcomes

Primary

Measure	Time frame
Non-bleeding survival time	—

Countries

Japan

Contacts

Public ContactHidaka Hisashi

Post-EVL Trial Post-EVL Trial Office

hisashi7@kitasato-u.ac.jp042-748-9111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026